A Multicenter prospective study of poor-grade aneurysmal subarachnoid hemorrhage (AMPAS): observational registry study by Bing Zhao et al.
Zhao et al. BMC Neurology 2014, 14:86
http://www.biomedcentral.com/1471-2377/14/86STUDY PROTOCOL Open AccessA Multicenter prospective study of poor-grade
aneurysmal subarachnoid hemorrhage (AMPAS):
observational registry study
Bing Zhao1, Xianxi Tan1, Hua Yang2, Kuang Zheng1, Zequn Li1, Ye Xiong1, Ming Zhong1* and AMPAS investigatorsAbstract
Background: Poor-grade aneurysmal subarachnoid hemorrhage (aSAH) is associated with very high mortality and
morbidity. Our limited knowledge on predictors of long-term outcome in poor-grade patients with aSAH definitively
managed comes from retrospective and prospective studies of small case series of patients in single center. The
purpose of the AMPAS is to determine the long-term outcomes in poor-grade patients with different managements
within different time after aSAH, and identify the independent predictors of the outcome that help guide the decision
on definitive management.
Methods/design: The AMPAS study is a prospective, multicenter, observational registry of consecutive hospitalized
patients with poor grade aSAH (WFNS grade IV and V). The aim is to enroll at least 226 poor-grade patients in
11 high-volume medical centers (eg, >150 aSAH cases per year) affiliated to different universities in China. This
study will describe poor grade patients and aneurysm characteristics, treatment strategies (modality and time of
definitive management), hospitalization complications and outcomes evolve over time. The definitive management
is ruptured aneurysm treatment. Outcomes at 3, 6, 12 months after the management were measured using the
Glasgow Outcome Scale and the Modified Rankin Scale.
Discussion: The AMPAS is the first prospective, multicenter, observational registry of poor grade aSAH with any
management. This study will contribute to a better understanding of significant predictors of outcome in poor
grade patients and help guide future treatment of the worst patients after aSAH.
Trial registration: Chinese Clinical Trial Registry: ChiCTR-TNRC-10001041.
Keywords: Aneurysmal subarachnoid hemorrhage, Poor-grade, Definitive management, Outcome, PredicatorsBackground
Aneurysmal subarachnoid hemorrhage (aSAH) is a sig-
nificant health problem with a mortality rate of about
60% within 6 months [1]. Although poor-grade aSAH
accounts for 20-30% of patients with aSAH [2], the over-
all good outcome with surgical or endovascular treat-
ment is only 33-56%, and mortality rate is 28–58% [3-5].
Poor-grade aneurysm patients received no surgical treat-
ment with 75-100% mortality [6,7]. Unlike good grade
aSAH, poor grade patients often have an acute brain in-
jury caused by severe cerebral swelling associated with* Correspondence: zhongming158@sohu.com
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unless otherwise stated.intracerebral hemorrhage [8], acute hydrocephalus or in-
traventricular hemorrhage [5], microcirculatory distur-
bances or decreased cerebral perfusion [9], and increased
intracranial pressure [10]. Therefore, the clinical presenta-
tion of poor grade aSAH is highly complex ranging from
comatose patients with or without midbrain symptoms
[11] to neurogenic cardiac and pulmonary dysfunction [9]
or final multi-organ failure. These differences in presenta-
tion also represent different severity of brain injury and
acute complications associated with aSAH. Therefore, it is
possible that careful selected patients with poor grade
could achieve good outcome after a patient-specific treat-
ment [7,12-14].
However, selection of patients for management on the
basis of the neurological condition remains controversialtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Zhao et al. BMC Neurology 2014, 14:86 Page 2 of 6
http://www.biomedcentral.com/1471-2377/14/86[15-17]. There are many different treatment modalities
in poor grade patients: aneurysm surgical treatment,
endovascular treatment, aggressive management of acute
hydrocephalus or ventricular hemorrhage without aneurysm
treatment, and conservative medication. Early treatment
(within 72 hours after aSAH) of patients with a good grade
on admission (WFNS I-III) prevents the rebleeding of
aneurysm and leads to a significantly better outcome [1].
However, recent studies have not identified a superior treat-
ment option for patients with poor grade aSAH. Although
some retrospective studies also demonstrated carefully se-
lected patients with early aneurysm treatment had a good
outcome, treatment strategies for poor grade aSAH are diffi-
cult to make between the family and the treating physician
owing to the high mortality and morbidity poor-grade aSAH
[18,19]. There have been two randomized treatment clinical
trials comparing endovascular and surgical treatment of
aSAH, particularly of good grade patients [20,21]. These re-
sults suggested a potentially better effect of endovascular
treatment than surgical treatment. However, there was a low
recruitment rate of poor-grade patients., and ISAT included
mostly good grade aSAH patients with small anterior circu-
lation aneurysms [22]. Nowadays the largest data on out-
come of patients with poor-grade aSAH was only a
retrospective case series of 283 patients [23]. But the retro-
spective study only determined the outcome at discharge
after surgical obliteration of the aneurysm. Whether poor
grade patients will benefit from advanced endovascular tech-
niques and materials is still unknown, therefore, which is a
better treatment strategy for poor grade aSAH still remains
controversial.
In addition, many selection bias and different condi-
tion grading and results of poor outcome described in
many studies exists in the literatures. Different defini-
tions of poor grade aSAH included Hunt& Huns grade
IV and V [4,6], WFNS grade IV and V [12,19,24]. The
grading scale was also measured either on admission or
before aneurysm treatment. Moreover, outcomes were
measured using the Glasgow outcome score (GOS) [13,16]
or the modified Rankin Scale (mRS) [25,26] at different
time of follow-up, and the good outcome was also identi-
fied differently [22,27], for example, good outcome was
identified as the mRs ≤2 or the mRS ≤3. These data in
small numbers of selected patients treated with definitive
treatments in a single center were collected for a retro-
spective study. Also, most patients treated over the past
several years or ten years in were also included in these
studies. There could be selection bias among retrospective
studies. Therefore, we could not make a good multivariable
analysis.
With advancements in early surgical treatment, endo-
vascular treatment, multimodality neuromonitoring and
multidisciplinary management, we need a better under-
standing long-term outcome in poor grade patients withindifferent treatment options within different time after
aSAH. Therefore, we performed the prospective multicen-
ter study on predictors of outcome in poor grade aSAH,
and we could further embark a suitable randomized trial
on the basis of registry data.
Methods/design
Study design
The AMPAS is a prospective, multicenter, non-randomized,
observational registry study of consecutive case series.
Eleven high-volume medical centers (eg, >150 aSAH cases
per year) that offers endovascular and microsurgical treat-
ment of aneurysm and neurological intensive care services
were included in the study. These academic centers are large
hospitals of different medical universities in China.
Ethical approval and governmental funding
The final study protocol and written informed consent were
approved by Chinese Ethics Committee of Registering Clin-
ical Trials (ChiECRCT-2010019). This study was funded by
the Chinese Ministry of Health (WKJ2010-2-016), Wenzhou
Bureau of Science and Technology (Y20090005). All in-
formed consent was obtained from the patient legal
representative.
Objectives
The key purpose of the AMPAS study is to determine
the long-term outcomes in poor grade patients with dif-
ferent managements within different time after aSAH,
and identify the independent predictors of the outcome.
That will help guide the decision on definitive manage-
ment of poor grade patients and the design of a future
randomized clinical trial.
This study will also determine the following questions:
(1) which clinical variables before and after any manage-
ment are associated with long-term outcome? Medical
history, clinical condition on admission, condition before
and after aneurysm treatment, aSAH CT grading scale,
aneurysm location and size, modality and time of definitive
management, and complications during the hospitalization.
(2) What are the most common complications related to
different managements (endovascular, microsurgical treat-
ment, and surgical management without aneurysm repair
or intensive monitoring and medication)?
Study population
Patients
All consecutive patients were diagnosed with SAH con-
firmed by head CT scans or lumbar puncture in the
emergency department. The patient condition was first
evaluated by neurosurgeons using the WFNS grade. If
the patient with WFNS grade IV and V was hospitalized
to be eligible for entry in the registry. But the following
inclusion and exclusion criteria were also applied.
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(1) age ranging from 18 to 75 years old.
(2) aneurysm confirmed by computed tomography
angiography (CTA) or digital subtraction
angiography (DSA).
(3) poor-grade patients with WFNS grade IV or V on
admission or before aneurysm treatment.




(1) withdrawing any managements in the emergency
department.
(2) SAH resulting from other reasons and unclear
diagnosis of aneurysm.
(3) aneurysm treated with endovascular or surgical
treatment at any other referring hospitals.
(4) pregnant or lactating women.
(5) loss of breath.
(6) patients with severe systemic disorders and
expected life span less than one year.
Detailed clinical data
Clinical variables included medical history such as hyper-
tension, smoking and diabetes, clinical condition after the
initial aSAH, on admission, before treatment, neurological
condition evaluated by the GCS, Hunt&Hess, WFNS grade,
herniation, ruptured aneurysm location and size, timing of
definitive management, treatment procedure recording,
neurological condition within 72 hours after the treatment,
complications during the hospitalization, follow-up imaging
and the presumed reasons of death. The total of hospital
expense was also recorded.
Management protocol
All eligible poor-grade patients were managed in neuro-
logical intensive care unit (NICU) according to the
guidelines for the management of aSAH [28,29]. The
management protocol included aggressive resuscitation
such as intubation and ventilation, microsurgical treat-
ment, endovascular treatment, surgical control intracra-
nial pressure using external ventricular drainage, and
neurological intensive care. Therefore, treatment modal-
ities were divided into two patterns: definitive manage-
ment of ruptured aneurysm; aggressive management
including only surgical treatment of hydrocephalus [5,25],
ventricular hemorrhage or intracranial hypertension, and
intensive monitoring and medication. Time of definitive
management was also grouped: ultra-early management
(within 24 hours after aSAH), early management (between
24 hours and 72 hours, late management (more than72 hours). Aneurysm treatment was discussed with cere-
brovascular surgeons and endovascular specialists based
on the patient age and aneurysm characteristics and loca-
tion. Treatment options were discussed between the fam-
ily and the treating physician. The final decision was made
by the family.
In general, surgical treatment of aneurysm was pre-
ferred for patients with aSAH associated with large
intracranial hematoma (>30 ml) and clinical signs of
brainstem compression. The treatment included aneurysm
clipping or wrapping, hematoma evacuation, or decom-
pressive craniectomy. Endovascular treatment of aneurysm
included aneurysm coiling, balloon or stent assisted coil-
ing, or a parent artery occluded. External ventricular drain-
age was inserted in patients with acute hydrocephalus or
ventricular hemorrhage before or after aneurysm obliter-
ation. All patients received intravenous nimodipine, Man-
nitol and hypervolemic, hypertensive, hemodilution (3H)
therapy after definitive management. Patients remained in
NICU until medically stable for transfer or until the family
terminated the treatment.
Follow-up and data quality
All patients will be followed up after the management by
a neurosurgeon using the telephone interview or in-
person interview. The neurosurgeon was trained before
the AMPAS registry and was not involved in the treat-
ment of poor-grade patients. Outcomes at 3, 6, and
12 months was measured using the GOS and mRS. The
mRS of 0–2 was identified as good outcome [22], and
the score of 3–6 is generally as poor outcome.
All data were collected using a written case report
form (CRF) and an electronic case report form (eCRF)
through a registry website using a center-specific login
and password. Meanwhile, data verification was under-
taken in 20% of all cases to assess the accuracy of data
recording. If the written CRF did not match eCRF, the
case record was excluded. If there were more than 5 pa-
tients excluded in the primary verification and more
than 5 patients without available clinical variables and
follow-up in the registry, All of patients in the center
were totally excluded at the time of database closure.
Sample size and data analysis
No data is available about the rate of poor outcome in
unselected population of poor grade patients. According
to previous literature, poor grade account for 20% of
aSAH [2], and poor come in selected patients after sur-
gical or endovascular treatment is about 55%. The target
number of patients included in the registry is at least
226 to identify the proposed 20 predictors of the out-
come with a two-sided significance level of 5%, a power
of 80% and an anticipated effect size of 0.10. The pri-
mary expected number of patients is more than 252 in
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Data was presented as mean and standard deviation for
continuous variables or frequency for categorical vari-
ables. Significances between variables were analyzed using
the t-test or Chi-square test. Association between clinical
variables and outcome will be analyzed, and predictors of
long-term outcome were identified using a univariate and
multivariate analysis. The difference was expressed as an
odds ratio (OR, with 95% confidence interval [CI]), and
significance was considered if P value was <0.05.
Discussion
The long-term outcomes in poor grade patients within
different treatment options within different time after
aSAH should be determined with advancements in de-
finitive management and multidisciplinary monitoring
and intensive care [30]. This study described poor-grade
patients with aSAH and aneurysm characteristics, treat-
ment strategies (modality and time of definitive manage-
ment), and hospitalization complications, and outcomes
evolve over time. The prospective multicenter study on
predictors of outcome in poor grade aSAH will be per-
formed, and a suitable randomized trial will be embarked
on the basis of registry data.
Predictors of poor outcome in poor-grade patients
have been demonstrated in several retrospective case
series studies [3,16,23,31] or few prospective case series
[26,32] over the decades. However, these results of pre-
dictors remain controversial with the small numbers of
patients in a single center [32] or selection bias such as
collecting patient data in different eras [26] or careful se-
lection of poor grade patients [13]. Only one prospect-
ive, multicenter trial of 184 poor grade patients in a
study of the calcium antagonist nimodipine in 1988
showed that factors prognostic for outcome were surgi-
cal treatment, neurological grade on admission, age, ini-
tial systolic blood pressure, and aneurysm size [18].
Another study using prospectively maintained SAH data-
base in single center between 1996 and 2002, only in-
cluded 40% of the 98 definitively treated patients. This
study demonstrated that significant predictors of poor
outcome were patient age older than 65 years, hypergly-
cemia, worst preoperative Hunt and Hess Grade V, and
aneurysm size of at least 13 mm. Also, a controlled obser-
vational study of 51 consecutive patients treated with
endovascular coiling within 96 hours of aSAH indicated
persistent intracranial pressure elevation and higher mean
8-day S100B value independently predicted the 1-year out-
come [32]. In addition, there was only one retrospective
review of large number of case series (283 cases) at mul-
tiple centers in Japan [23]. But the study only identified
the independent predictors of outcome at discharge in-
cluding advanced age, WFNS grade V, improvement in
WFNS grade, and low-density area associated withvasospasm on CT, whereas rebleeding, early aneurysm
surgery and treatment modality (surgical clipping or
coil embolization) were not independently associated
with outcome in poor-grade Patients [23].
Although, there is one ongoing prospective, single-
center, observer-blinded, randomized controlled trial to
determine optimal timing for surgery in poor-grade pa-
tients [33], and one pragmatic, multicenter, randomized
trial comparing clinical outcomes for patients with
aSAH allocated to coiling or clipping [22], evidence for
the predictors of long-term outcome in poor grade pa-
tients has not been provided so far. Moreover, a recent
systematic review also showed clinical prediction models
for aSAH used a few simple predictors and have not had
external validation for clinical or research purposes [34].
Therefore, and further study will be validated reliable
prediction models for poor grade aSAH.
In conclusion, the AMPAS study will be the first pro-
spective, multicenter, observational registry of poor grade
aSAH with any management worldwide, particularly in
China. This study will contribute to a better understand-
ing of significant predictors of outcome in poor grade
patients and help guide future treatment of the worst
patients after aSAH.
Current status
Between October 2010 and March 2012, 366 poor-grade
aSAH patients have been entered. The last patient
follow-up at 12 months was completed until March
2013. Data of 76 patients in 2 centers were totally ex-
cluded at the time of database closure according to data
quality policy because clinical variables and follow-up
were lost. At last, Of 293 poor grade patients on admis-
sion or before aneurysm treatment in the registry, 168
patients with WFNS grade IV, and 125 patients with
WFNS grade V were included.234 patients (80%) were
definitively treated with surgical treatment(103patients)
and endovascular treatment (131 patients). 20 patients
only received aggressive management including external
ventricular drainage, and hematoma evacuation and de-
compressive craniectomy.39 patients only received neu-
romonitoring and medical treatment.
Appendix
AMPAS Investigators
Hongqi Zhang, Beijing Xuanwu Hospital affiliated to
Capital Medical university; Chuangsheng liang, China Med-
ical University;Huaizhang Shi, Harbin Medical University;
Jin XU, Zhejiang Medical University;Li Pan, Wuhan Gen-
eral Hospital of Military Medical University;Xin Zhang,
Nanjing General Hospital of Military Medical University;
Gang Zhu, West South hospital of the Third Military
Medical University; Jianping Deng,Tangdu Hospital of the
Fourth Military Medical University.
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